Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain LJPC message board posts where the ticker symbol LJPC has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest LJPC SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 5.02 and 5.07
Acc-no: 0000920465-18-000035 (34 Act)  Size: 37 KB
2018-09-18 001-36282
181074531
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0000920465-18-000032 (34 Act)  Size: 1 MB
2018-08-22 001-36282
181032845
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000920465-18-000029 Size: 4 KB
2018-08-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000920465-18-000028 Size: 4 KB
2018-08-20
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000920465-18-000026 (34 Act)  Size: 2 MB
2018-08-08 001-36282
181001488
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0000920465-18-000025 (34 Act)  Size: 172 KB
2018-08-08 001-36282
181001337
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000920465-18-000019 Size: 6 KB
2018-06-01
8-K  Documents Current report, items 1.01, 2.02, 2.03, and 9.01
Acc-no: 0000920465-18-000018 (34 Act)  Size: 675 KB
2018-05-14 001-36282
18831925
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000920465-18-000015 (34 Act)  Size: 1 MB
2018-05-10 001-36282
18823188
10-K/A  Documents [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0000920465-18-000011 (34 Act)  Size: 638 KB
2018-04-30 001-36282
18791536
More LJPC SEC Filings


Related news from
Thu, 16 Aug 2018
12:00:00 +0000
Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX — New Research Emphasizes Economic Growth
NEW YORK, Aug. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celsion ...
Mon, 13 Aug 2018
19:35:00 +0000
Edited Transcript of LJPC earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 La Jolla Pharmaceutical Co Earnings Call
Thu, 09 Aug 2018
16:51:00 +0000
Why La Jolla Pharmaceutical Is Tumbling Today
Shares drop off after the company reports second-quarter results that left investors wanting more.
Thu, 09 Aug 2018
00:00:12 +0000
La Jolla Pharmaceutical (LJPC) Reports Q2 Loss, Misses Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -5.76% and -35.64%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Wed, 08 Aug 2018
22:55:31 +0000
La Jolla Pharmaceutical: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of $2.02 per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
Wed, 08 Aug 2018
20:01:00 +0000
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
SAN DIEGO, Aug. 08, 2018-- La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering ...
Wed, 08 Aug 2018
18:30:00 +0000
La Jolla Pharmaceutical Company to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / La Jolla Pharmaceutical Company (NASDAQ: LJPC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 ...
Fri, 03 Aug 2018
13:00:00 +0000
La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for GIAPREZATM (angiotensin II) Injection for Intravenous Infusion. GIAPREZA is indicated to increase blood pressure in adults with septic or other distributive shock. The CMS NTAP program provides additional reimbursement to hospitals beyond the Medicare Severity Diagnosis-Related Group (MS-DRG) reimbursement for specific products that meet strict criteria for the treatment of Medicare patients.
Wed, 01 Aug 2018
21:39:42 +0000
La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018
SAN DIEGO, Aug. 01, 2018-- La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering ...
Mon, 16 Jul 2018
11:05:00 +0000
Free Technical Research on Marinus Pharma and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
Mon, 25 Jun 2018
13:00:00 +0000
La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA™ (angiotensin II)
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Marketing Authorisation Application (MAA) for GIAPREZA (angiotensin II) Injection for Intravenous Infusion was validated by the European Medicines Agency (EMA). Validation of the MAA confirms that the submission is complete and starts the EMA’s centralized review process. La Jolla submitted the GIAPREZA MAA for the treatment of hypotension in adults with distributive or vasodilatory shock who remain hypotensive despite fluid and vasopressor therapy.
Fri, 15 Jun 2018
18:39:50 +0000
2 Stable and 2 Speculative Biotech Stocks to Buy
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
Fri, 15 Jun 2018
11:09:00 +0000
Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar
Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...
Fri, 11 May 2018
11:05:00 +0000
Complimentary Stock Performance Review on La Jolla Pharma and Three Additional Biotech Industry Stocks
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Immune Design Corp. (NASDAQ: IMDZ), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX).
Fri, 11 May 2018
01:23:29 +0000
What Should We Expect From La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) Earnings In The Next Couple Of Years?
The latest earnings release La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) announced in December 2017 showed company earnings became less negative compared to the previous year’s level as a result of recentRead More...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "No friend, no book, no broker, no advisor, no expert has ever provided a tenth what I am able to find here. The best money I have EVER spent, is for membership." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards